Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|CFI-400945||CFI-400945 is a selective Polo-like kinase 4 (PLK4) inhibitor that inhibits cell division and induces apoptosis in tumor cells (PMID: 25043604, PMID: 31303643).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||not applicable||CFI-400945||Phase I||Actionable||In a Phase I trial, treatment with CFI-400945 was tolerable and resulted in a clinical benefit rate of 6% (3/49; 1 partial response and 2 stable disease) in patients with advanced solid tumors, with 1 partial response in a patient with adenoid cystic carcinoma, and stable disease in 1 patient with KRAS-mutant microsatellite stable (MSS) colorectal cancer lasting 12 cycles with a 24% reduction in target lesions, and 1 patient with MSS ovarian cancer lasting 8 cycles (PMID: 31303643; NCT01954316)||31303643|
|SMARCB1 loss||atypical teratoid rhabdoid tumor||sensitive||CFI-400945||Preclinical - Cell culture||Actionable||In a preclinical study, CFI-400945 inhibited proliferation and decreased survival and migration of SMARCB1-deficient atypical teratoid rhabdoid tumor cells in culture (PMID: 28398638).||28398638|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03624543||Phase II||CFI-400945||CFI-400945 in Patients With Advanced/Metastatic Breast Cancer||Recruiting||CAN||0|
|NCT03187288||Phase I||CFI-400945||A Study of CFI-400945 Fumarate in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome||Recruiting||CAN||0|
|NCT01954316||Phase I||CFI-400945||A Study of CFI-400945 Fumarate in Patients With Advanced Cancer||Active, not recruiting||USA | CAN||0|